Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma

While we await the overall survival data for ZUMA-7, the mature ZUMA-1 data shows the curative potential of Axi-cel (Yescarta) for relapsed/refractory DLBCL.

Takeaway from TFOC:
– Best response CR in 59% –> many will still relapse!
– Long term CR in 30% –> CURE!

Read the full article here

Related Articles